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Background: An unceasing threat of drug resistance continuously poses demand for new antimalarial
drugs. A scientiﬁc assessment of traditionally used antimalarial plants through reverse pharmacology is
crucial for a fast track drug discovery. An Ayurvedic plant Nyctanthes arbor-tristis Linn. e (Parijat) is being
used in clinical practice and had shown antimalarial activity, with a parasite clearance in 76.6% of 120
patients, in an earlier clinical study.
Objective: To further explore antimalarial potential of the plant through additional objective markers.
Materials and methods: An open-labelled observational study was conducted at M.A. Podar Hospital e
Ayurveda (MAPH-A) after ethics committee approval. Administration of a paste of 5 fresh leaves, thrice a
day for a week was a standard practice for management of malaria at MAPH-A. Clinical activity of
N. arbor-tristis was evaluated by monitoring pyrexia, parasitemia and morbidity score (MS) in twenty
patients. In addition, immune and biochemical markers and organ functions were monitored for
objective markers of response. Student's paired-‘t’ test was applied to assess statistical signiﬁcance.
Results: Ten out of 20 patients showed both fever and parasite clearance, which was conﬁrmed by po-
lymerase chain reaction. Remaining ten patients had persistent but decreasing parasitemia. Four of them
needed chloroquine as a fail-safe procedure. Irrespective of the degree of parasitemia all the patients
showed decrease in MS. There was also an increase in platelet count and normalization of plasma lactic
acid. There was a good clinical tolerability and an improvement in organ function. The inﬂammatory
cytokines showed a reduction; particularly in TNF-a within a day.
Conclusions: At the given dosage, N. arbor-tristis showed disease-modifying activity; early clinical re-
covery with a decline of TNF-a and a gradual parasite clearance. Further studies with a standardised
formulation for dose-searching and optimizing the treatment schedule are needed in a larger sample size.
Clinical trial registration no: The process of trial registration had not begun when the study was
conducted in 2000.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
In the last decade, 40% of the malaria-endemic countries re-
ported reduction in the incidence of malaria by half. This has raised
hopes to the stage of ‘complete eradication’ of malaria in the nearary University, Bangalore.
alore and World Ayurveda Found
censes/by-nc-nd/4.0/).future. Recently, the World Health Organization (WHO) announced
an ambitious new plan to “almost” eradicate malaria by 2030; 40%
by 2020 and 90% by 2030 [1]. However, alarming reports of arte-
misinin resistance, ﬁrst from Thai-Cambodian border in 2009 and
it's spread in 5 countries within 5 years have contributed to the
unceasing threat of resistance development [2,3]. This has put forth
again an urgent need for the development of new antimalarial
drugs. In spite of persistent efforts and signiﬁcant investment,
availability of long lasting antimalarial drugs is still a quest.ation. Publishing Services by Elsevier B.V. This is an open access article under the
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major attraction for drug discovery scientists. The two major anti-
malarial drugs; artemisinin and quinine, have been discovered
from plants. However, efforts through extensive research on me-
dicinal plant have been largely unproductive due to the smash and
grab approach as articulated by Wells TN [4]. In the present study
we have explored antimalarial potential of traditionally used Ay-
urvedic plant e Nyctanthes arbor-tristis Linn. (N. arbor-tristis) e
family Oleaceae; through Reverse Pharmacology (RP).
RP has been recently evolved, in India, as a fast-track trans-
disciplinary research and development path to discover and
develop a standardized formulation, extract or active principle e
from Ayurvedic medicinal plants of therapeutic importance [5]. It is
deﬁned as ‘The science of integrating documented clinical experiences
and experiential observations (hits) into leads by trans-disciplinary
exploratory studies to further develop these into drug candidates or
formulations through robust preclinical and clinical research’. RP is
one of the paths of drug development from traditional medicine,
which essentially relates to reversing the standard “laboratory to
clinic” progress of the discovery pipeline to “clinic to laboratory” or
“bedside-to bench” approach [5,6].
N. arbor-tristis a sacred plant from India, has been described for
its use in vishamjwara (malaria) in the classical text [7], and for
malaria in notes of Aryavaidya Mayaram Sundarji [8], Waman
Ganesh Desai [9] and several others (Fig. 1). Vaidya Antarkar and
Vaidya Tathed at MAPH-A had introduced the use of N. arbor-tristis
in the management of malaria, as an Ayurvedic line of treatment.
Chloroquine (CQ) was used when there was failure of response to
this treatment or in severe cases. The early clinical observations of
the antimalarial activity and safety of the plant were recorded
during MD (1995) and PhD (1997) thesis work by Karnik [10]. In
that collaborative experiential study (published in 2008), we have
reported antimalarial activitye clinical cure and parasite clearance,
in 92 of 120 patients (76.7%), when treated for 7e10 days with the
paste of the fresh leaves of the plant (as a traditional dosage form)
[11]. Clinically, cure was associated with not only the fever clear-
ance but also an early decrease in the severity of all malaria-related
symptoms. That experiential study was followed by systematic
exploratory studies in clinic and laboratory. The present study is
being published after a delay as there was an ongoing experiment
to generate intellectual property rights (IPR) vis-a-vis disease-
modifying novel action demonstrated by objective markers of
response. (In view the uncertainty of a precise phytoactive, despiteFig. 1. Shows description in classical texts for the use of N. arbor-tristis. Sanskrit shloka
[7] (Top): Dalarasa, Juice of leaves of N. arbor-tristis (Shefali) in malaria (Vishamjwara),
Notes in Gujarathi [8] (Left): Parijat, Harshringara pan … N. arbor-tristis leaves,
Malarainu Tavane… in malarial fever, ‘Aushadhisamgrah’ [9] in Marathi (Right): Dosage
form: Tajya panacha amgarasa: juice of fresh leaves. Lohabhasma may be added for
anaemia. Excess milk, ghee and sugar intake recommended.substantial isolation efforts, the attempt for IPR is dropped.) The
parasite clearance was conﬁrmed by the use of polymerase chain
reaction (PCR) for the absence of Plasmodium species. Markers for
organ functions, and inﬂammatory severity were assessed for
tolerability, and disease-modifying activity respectively.
2. Material and methods
2.1. Patient material
The present observational study of N. arbor-tristis was carried
out during rainy season (June 2000 to Aug 2000), at the peak of
malaria incidence within the endemic area eWorli, Mumbai, at the
same hospital i.e. MAPH-A a postgraduate teaching institution.
Patients were strongly suspected to have malaria based on their
clinical presentation. In view of the antimalarial activity shown in
76.7% of 120 patients in an earlier experiential study, the number of
patients for screening was decided to be thirty. A sample size of
completed twenty patients was considered to be adequate with a
more frequent and detailed clinical and parasite monitoring by
rigorous methods of assessment.
2.2. Preparation of paste of N. arbor-tristis
Fresh leaves ofN. arbor-tristiswere obtained from a single tree in
the garden of MAPH-A as described earlier [10,11]. The plant was
identiﬁed by the botanist. Medium-sized leaves were plucked by a
trained attendant every day, washed with distilled water and
crushed in mixer for fresh preparation of the paste. The paste was
then distributed in small containers equivalent to a single dose (5
leaves approx. wt. 6.8 to 7 gm) per container and used fresh for the
day.
2.3. Study design
An open-labelled observational study of exploratory stage of
Reverse Pharmacology; with baseline as control was chosen for the
individualized in-depth evaluation. Protocol, case record form
(CRF) and informed consent form were approved by the indepen-
dent ethics committee e Inter-Systems Biomedical Ethics Com-
mittee (ISBEC) of Mumbai. The informed consent form in regional
language comprised of the information of the study, risk and ben-
eﬁts to the patient, and patients’ responsibility and rights during
the study. The Ayurvedic experts of the ISBEC approved the drug
administration at the Ayurvedic hospital under the guidance of an
expert Ayurvedic physician (PSTeone of the co-authors), as per the
Good Clinical Practice Guidelines by Indian Council of Medical
Research.
2.4. Selection criteria
Patients visiting the outpatient clinic of MAPH-A, with age be-
tween 15 and 55 years, presenting fever and chills, were screened
and selected if conﬁrmed to have malaria (Plasmodium falciparum
and/or Plasmodium vivax) by microscopy and by a rapid diagnostic
test (RDT), OptiMal™. The severity of malaria in selected patients
was mild to moderate with the haemoglobin value > 8 gm % and
absence of cerebral or renal complications. Patients having other
systemic diseases or on drugs were excluded.
2.5. Enrolment of patients
The study details were explained to patients in their language as
to the drug information, study procedure, the degree of inconve-
nience due to frequent venipunctures, temperature recording and
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enrolled, only if they agreed to participate in the study, after taking
their written informed consent and were admitted to the Kaya-
chikitsa (Internal Medicine) ward. In case of patients below 18 years
old (n ¼ 2), consent was given by the parents.
2.6. N. arbor-tristis administration
Each patient was provided three containers with a ﬁxed dosage
of the paste of leaves for the day and was explained to ingest the
dose under supervision at 9 am, 1.30 pm, and at 9 pm i.e. after
breakfast, lunch and dinner respectively. The duration of the
treatment was for a minimum period of 7 days. The treatment was
continued beyond 7 days till the complete cure, only in those pa-
tients, whowere showing improvement. This was decided based on
the clinical judgement of the Ayurvedic expert (PSTeone of the co-
authors). Compliance was monitored by the nursing staff and the
resident physicians. No other antimalarial or anti-pyretic drugs
were administered during the study. In case of high fever, non-drug
modalities like tepid sponging, cold water enema were used.
2.7. Criteria of clinical response
Clinical response to N. arbor-tristis was monitored daily by
assessing the reduction in the severity of the twenty target features
of malaria (Table 1 in result section). These target features were
chosen based on the high frequency of the dominant signs and
symptoms noted in the earlier larger experiential study of 120
patients. These features were graded individually for their severity
on every day as: absent¼ 0, mild¼ 1, moderate¼ 2 and severe¼ 3.
The MS was calculated for each patient as the sum of the severity
scores of all the twenty symptoms and signs daily. The mean
morbidity score (MMS) at the baseline and on each day till 7th day
of the treatment for all patients was calculated for the analysis of
the clinical response. Apyrexia as one of the criteria of the clinical
response was determined by a careful record of temperature by ear
thermometer at every 2 h excluding sleep hours. Consistent tem-
perature of 98 F for consecutive three days was considered a
complete fever clearance.
2.8. Assessment of antiparasitic activity
The change from the basal parasite count was monitored on the
days 1st, 3rd and 7th, and the absence of parasites was considered
as a parasitic cure. The parasite clearance was judged by blood
smear examination, RDT (OptiMal™) and conﬁrmed by PCR on the
preserved blood dry blots in all the twenty patients (vide infra). PCR
was done by one of the authors (CG) at the Centre of Molecular
Parasitology, Drexel University, Philadelphia, USA.Table 1
Target features of malaria: Baseline frequency and change by 7th day.
Symptoms and signs Frequency (n)
Baseline 7th day
Fever 20 6
Nausea 20 3
Chills 18 0
Headache 18 7
Anorexia 17 1
Bodyache 17 4
Exhaustion 16 1
Vomiting 16 2
Bitterness of mouth 14 5
Loss of taste 14 6
n: Number of patients; out of 20, showing the symptoms at the baseline and on 7th day2.9. Criteria of tolerability assessment
The clinical tolerability of the paste of N. arbor-tristis was
assessed by a careful daily monitoring of the adverse events and
physical examination. Adverse events were evaluated and the
causality was ascribed as per the criteria of Karch and Lasagna [12].
Any new symptom, sign or a marked change in organ function test,
after intervention and not expected to a natural history of malaria
was considered as adverse drug event (ADE). ADEs were recorded
as to their onset, severity and duration. Measures taken for the
assessment and treatment of ADE were recorded. Laboratory in-
vestigations (day 0, 1st, 3rd, 7th) viz. complete blood count and
markers of liver and kidney functions for the organ safety were
carried out.
2.10. Fail-safe procedures
In the situation where patient failed to respond, had severe
aggravation of pyrexia or severe side effects the patient was to be
discontinued from the study and prescribed standard CQ therapy.
In addition, if patient chooses towithdraw from the trial CQ therapy
was to be prescribed.
2.11. Parasite identiﬁcation and count: microscopy, rapid test and
PCR
Venous blood was collected from the antecubital vein, in vacu-
tainers with EDTA, on day 0, 1st, 3rd and 7th of the treatment for
parasite counts. Thin blood smears were stained with Giemsa by
using standard method and a number of infected RBCs were
counted in total 2000 RBCs/slide. The percent parasitemia was
estimated as described previously [11]. RDT was also used to
conﬁrm presence of parasite and its type. Parasite clearance during
the treatment period was monitored by both microscopy and RDT.
Blood samples were preserved for PCR, in the form of dry-blots, on
the Whatman Paper No. 1. Deoxyribonucleic acid (DNA) was
extracted from the dry blots by the method described by Newbold
et al. [13]. In brief, the dry blot was washed with phosphate buff-
ered saline followed by incubation with saponin. Then the blot was
boiled with alkaline chelex-100, thenwas smashed with pipette tip
to release DNA. The extracted DNA in supernatant was obtained by
centrifuging the mixture. The DNAwas subjected to nested PCR for
the ampliﬁcation of P. vivax-speciﬁc Merozoit Surface Protein–3a
(MSP-3a) gene [14] and P. falciparum-speciﬁc Glutamate Rich Pro-
tein (GLURP) antigen gene [15].
2.12. Reagents, chemicals and instruments
The RDT kit e OptiMal™ from Flow INC, Philadelphia, was
supplied by Global Diagnostic, Mumbai. Giemsa stain was obtainedSymptoms and signs Frequency (n)
Baseline 7th day
Excessive sweating 11 1
Thirst 10 3
Body heaviness 10 2
Abdominal pain 8 3
Giddiness 7 0
Splenomegaly 7 7
Lethargy 6 0
Cough 6 0
Hepatomegaly 6 6
Anaemia 4 4
.
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lactic acid Spineract SA, Espana; human tumour necrosis factor
(TNF)-a, Interleukin (IL)-10 and IL-6, Interferon-g (IFN-g) R & D
system e Quantikine®; C-reactive protein (CRP) Nycocard Single
test, Axis-shield, Norway; biochemical test kits viz. ALT, creatinine,
ERBA Test, Transasia Bio-Medicals, India.
The following instruments and accessories were used for
various studies viz. Sysmex K 1000 Haematology analyser (TOA
Medical electronics Co. Ltd. Japan) for haemogram and platelet
count; Semi-auto analyser (ERBAChem Pro) for biochemical
markers; Labomed Vision 2000 Microscope for parasite identiﬁ-
cation and count; Nycocard Reader II for CRP, Stat Fax 303 Plus,
Awareness Technology INC an enzyme linked immunosorbent
assay (ELISA) reader for cytokines and interleukin assays. Vacu-
tainers for blood collection were obtained from Becton Dickinson.
An ear thermometer (ThermoScan PLUS, Germany) was used for
monitoring internal body temperature.2.13. Statistical analysis
The values of all the investigations were calculated for means
and standard error (mean ± SE). The levels of statistical signiﬁcance
were determined by applying the student's paired ‘t’ test by using
GraphPad Prism 5 software.3. Results
3.1. Baseline proﬁle of patients and symptomatic response
Total 30 patients of fever and chills were screened and diagnosis
of malaria was conﬁrmed in 27 patients by microscopy andFig. 2. Shows clinical response (apyrexia) and parasite clearance in subset A and B. All the
improvement and parasite clearance ** Clinical improvement but parasite present # DischaOptiMal™. Twenty of them agreed to follow the study protocol and
hence were enrolled for the study.
The baseline syndromic proﬁle of the patients was done for
twenty target features of malaria. Table 1 shows the frequency of
these features. While fever and nausea were present in all patients,
other most frequent symptoms were chills and headache (n ¼ 18),
body ache, anorexia (n ¼ 17), exhaustion and vomiting (n ¼ 16),
bitterness of mouth and loss of taste (n ¼ 14), and excessive
sweating (n ¼ 11). Ten patients had thirst and body heaviness.
Remaining symptoms were less frequent, as shown in Table 1. None
of the patients had drowsiness or mental changes. P. vivax infection
was detected in 8 patients and P. falciparum in 9 patients. The
remaining three patients having mixed infection were positive for
both the parasites.
All the twenty patients; irrespective of the type of plasmodial
infection and the degree of parasite count, showed distinct symp-
tomatic improvement, began from day 1 (24 h) of the treatment.
Table 1 also shows change in frequency of all the symptoms with
treatment of 7 days.3.2. Antimalarial activity of N. arbor-tristis: fever and parasite
clearance
Antimalarial activity of the plant paste was assessed by clinical
response that comprised of apyrexia and parasite clearance. The
results are summarized in Fig. 2. Based on these data, patients were
divided in to two subsets: subset A and subset B as cured and
partially responded respectively.3.2.1. Subset A
This subset comprised of 10 patients (4 P. falciparum, 4 P. vivax
and 2 mixed infection) out of 20 who showed complete cure bypatients were treated with the paste of fresh leaves of N. arbor-tristis. (* Both clinical
rge against medical advice as patients were not willing to continue.
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had fever clearance within 7 days and six of these 7 also had
parasite clearance by 7 days. One of these 7 patients showed
parasite clearance on 15th day of treatment. Remaining 3 of 10
patients, on continuous treatment beyond 7 days showed fever
clearance by 9e12 days. Parasite clearance in these 3 patients was
between 14 and 30 days of treatment.
3.2.2. Subset B
Patients in this subset (n ¼ 10) were showing directionality in
the clinical response. Six of these 10 cases showed apyrexia e 5
within 7 days and 1 took 10 days. These 6 patients however, had
persistent but decreasing parasitemia. These patients were not
willing to stay in hospital and were discharged against medical
advice (DAMA) between 8th to 13th day of treatment. Though these
patients were advised to take standard CQ regimen, their follow up
after CQ was not available. The four remaining patients; due to
repeated fever episodes were shifted to standard CQ regimen
during 7e16 days as per the fail-safe procedure.
In-depth comparative analysis was carried out, for the selected
objective markers in subset A and subset B. The objective markers
analysed during the 7 days of treatment were MS, parasite count,
platelet count and lactic acid, TNF-a, CRP and organ functions.
Parasitemia and MS were monitored until discharge (beyond 7
days).
3.3. Antimalarial activity of N. arbor-tristis: MS and parasite count
The symptomatic response was semi-quantitatively judged by
change in the MS and fever clearance. The decrease in MS was
associated with the decrease in severity of all the major symptoms
shown in Table 1. However in the short period of 7 days observa-
tion, there was no remarkable change in hepatosplenomegaly.
Parasite count monitored in these patients on day 1st, 3rd and 7th
showed gradual decrease from the baseline count. The scatter gram
for the MS and parasite count in these patients are shown in Figs. 3
and 4 respectively.Fig. 3. Shows MS in two subsets A and B at 0'D (baseline) and on every day thereafter for 7
score for 20 malaria related markers in each patient. Drop in MMS was highly signiﬁcant iBoth the subsets had similar MS at the baseline (subset A
19.8 ± 1.9 and 19.4 ± 1.5). A signiﬁcant reduction; > 50% in MS
(p < 0.0005 and p < 0.0001 in subset A and B respectively) was seen
within 24 h of treatment. A further drop in MMS was signiﬁcant on
7th Day in both the subsets as 4.1 ± 0.7 in subset A and 4.0 ± 1.2 in
subset B (p < 0.0001).
Mean parasite count was monitored in both the subsets. Mean
baseline parasite count in subset A was 0.62 ± 0.24% and of subset B
was 0.39 ± 0.1%. Six patients from Subset A cleared parasites and
remaining four patients showed a decrease by 7th day. Remaining
four patients continued treatment beyond 7 days and showed com-
plete clearance between 14 and 30 days (vide infra). Subset B showed
marginal decrease in parasite count on 7th day (0.31 ± 0.12%), which
was not signiﬁcant from the baseline mean count 0.39 ± 0.03%.
Parasite clearance in these patients was conﬁrmed by PCR. Fig. 5
shows representative data e Ampliﬁed DNA on agarose gel
electrophoresis.
A signiﬁcant correlation was found in MS and parasite count at
baseline (p < 0.05 and Spearman r ¼ 0.44) in 20 patients. This
correlation did not remain signiﬁcant (Spearman r ¼ 0.033) on
7th day. This indicates discordance between MS and parasite
clearance, due to early clinical response despite presence of para-
sites during treatment.
In addition there was no association of the baseline MS or
parasite count with the type of species or with the therapeutic
response. Individual analysis of 4 delayed responders from subset A
distinctly showed this feature. Two of the 4 delayed responders
from subset A had very high parasitemia at base line. The patient
having highest baseline parasitemia as 2.35% also had the highest
MS as 31 with P. vivax infection. Another patient had baseline
parasite count 1.58%, with MS 23 and was positive for P. falciparum.
They showed a decrease in parasite count as 0.13% and 0.18%
respectively on the 7th day and complete parasite clearance by 14th
and 30th day. Other two delayed responders from subset A had
mixed and P. falciparum infection with MS 19 and 22 and baseline
parasitemia 0.3% and 0.5% respectively. These patients showed
parasite clearance by 15th and 22nd day respectively.days during the treatment with N. arbor-tristis. MS was calculated by adding severity
n both the subsets, suggesting clinical improvement.
Fig. 4. Shows parasite count in subset A and B that was monitored by microscopy on day 0, 1st, 3rd and 7th day of treatment with N. arbor-tristis. Parasite count was done by
counting infected RBCs, against 2000 RBCs. Subset A showed signiﬁcant drop in parasite count by 7th day, with complete clearance in six patients.
Fig. 5. Shows representative electrophoretic run of PCR product: PCR was done for diagnosis and monitoring of parasite clearance in patients treated with N. arbor-tristis. Speciﬁc
primers for gene – MSP-3a for P. vivax (Top) and GLURP for P. falciparum (Bottom) were used. Lane i.d. is indicated on the top of each lane as Patient #/day of sampling. The presence
of band indicates that sample was positive and absence of band indicates negative for parasite. Note two mixed infections Pt. 05: þve for P. vivax on 0 day and 1'day of treatment
then became negative ; the P. falciparum infection came up by day 7, which cleared on day 15 (data not shown), this patient was clinically normal by day 7. In other patient (#13),
mixed infection was detected on 0 day e P. vivax got cleared by day 3 and P. falciparum got clear by day 1, clinically this patient was normal by day 2.
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Decrease in platelet count and increase in lactic acid levels is
associated with the pathogenesis of malaria. These pathological
markers were monitored in patients of subset A and B. Figs. 6 and 7
show comparative data. Low baseline mean platelet count was seen
in both the subsetse subset A: 64.2 ± 11.9 103/mm3 and in subsetB 80.38 ± 19.1  103/mm3 (Normal range 150  103/
mm3e450  103/mm3). Both the subsets showed increasing trend
in platelet count by 7th Day as 188.4 ± 37.2  103/mm3 and
105.7 ± 24.8  103/mm3. However, the increase was signiﬁcant
(p < 0.005) in subset A (Fig. 6). Out of total 18 patients, in whom
platelet count was available, 16 had baseline count below normal.
Irrespective of MS, parasite type and count, out of these 16 cases 11
Fig. 6. Shows platelet count in subset A and B. The dotted lines in the graphs show normal range. Increasing trend was seen in 11 patients and 8 returned to normal platelet count
by 7th days.
Fig. 7. Shows lactic acid levels in subset A and B during treatment. Signiﬁcant drop in mean lactic acid levels was seen in Ssubset A. The dotted lines in the graphs show normal
range. Eight patients from both the subsets had high lactic acid levels, above normal range, all of them showed signiﬁcant decrease by 7th day.
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7 days.
Mean lactic acid measured at baseline was high (Fig. 7):
28.2 ± 5.4 mg/dl and 18.2 ± 3.8 mg/dl in subset A and B respectively
(normal range 9e16 mg/dl). Both the subsets showed decrease in
lactic acid by 7 days, though not signiﬁcant. Out of total 17 patients,
in whom lactic acid levels were available, 8 had baseline high value
(34.2 ± 4.2 mg/dl). All these 8 cases (6 from subset A and 2 from
subset B) showed signiﬁcant decrease to 13.3 ± 1.4 mg/dl by day 7
(p < 0.005).3.5. N. arbor-tristis: effect on organ function
Serum levels of ALT, AST, alkaline phosphatase, protein and al-
bumin were measured to monitor liver function. Blood urea ni-
trogen (BUN), uric acid, creatinine were measured to monitor
kidney function in 17 patients during the treatment. All these 17
patients, irrespective of their clinical response showed baseline
abnormal levels of one or more of these markers, indicating liver
&/or kidney dysfunctions. All the patients showed improvement in
organ function markers (vide infra).
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Four patients had high ALT (58e501 IU/L) and 10 had high AST
(44e409 IU/L) at the time of admission. Both these liver enzymes
showed decreasing trend from day 1 itself. On the 7th day ALT
levels were in the range of (25e60 IU/L) and AST levels were
(19e69 IU/L). The synthetic function of the liver was found to be
affected either at the baseline as albumin was low in all 15 patients
and protein was low in 10 patients. During the treatment with N.
arbor-tristis, 11 patients showed an increase in albumin and 8 pa-
tients showed increase in protein by 7th day. Alkaline phosphatase
measured in all these 15 patients was within normal range (sup-
portive data is given in a Supplementary File).3.5.2. Kidney function
Kidney function was found to be affected in 8 patients as one or
more marker of kidney function showed abnormal levels. Six pa-
tients had high BUN (4e87 mg/dl) and 5 patients had high uric acid
(6.9e9.4 mg/dl). All of them showed normal levels by 7th day of
treatment as BUN (19e26 mg/dl) and uric acid (3.9e6.6). One pa-
tient had high baseline creatinine (2.5 mg/dl) which reduced to
1 mg/dl by day 7 (supportive data is given in a Supplementary File).
None of the 17 patients showed aggravation of liver or kidney
functions during the treatment.3.6. N. arbor-tristis: effect on inﬂammatory markers
TNF-a; an inﬂammatory cytokine, showed drop from baseline in all
patients (n ¼ 16) from both the subsets. The drop within 24 h of
treatment was signiﬁcant in patients from subset A. Similar drop was
also seen in subset B, even though not signiﬁcant (Fig. 8). Similarly IL-
10, an anti-inﬂammatory cytokine, studies in these patients showed
drop by 7 days, signiﬁcantly in both the subset (p < 0.005 and < 0.05
respectively) (Fig. 9). It was observed that the drop in IL-10 was
gradual and higher levels were maintained for a longer period,
compared to the drop on TNF-a. CRPmeasured in all these 16 patients
also showed baseline high value. Baseline mean CRP in subset A was
85.1 ± 13.5 mg/L and in subset B was 77 ± 15.3 mg/L. Both subsetsFig. 8. Shows levels of TNF-a; an inﬂammatory cytokine in subset A and B during the treatm
statistical signiﬁcance was seen in subset A.showed decrease in CRP on 7th day as 46.5± 16.3mg/L and 52.7± 14.2
(p < 0.05) (supportive data is given in a Supplementary File).
3.6.1. Tolerability
Not withstanding the bitter taste, the acceptance of the
formulation was good and the baseline symptoms of nausea and
bitter test due to malaria were relieved. Organ function test did not
show any adverse reaction in any of the patient. The safety and
tolerability of N. arbor-tristis in all these patients were closely
monitored clinically as well as with the laboratorymarkers of organ
functions. None of them showed any adverse event except one
patient who developed, on the 7th day mild but self-limiting
diarrhoea.
4. Discussion
Medicinal plants, used in Ayurveda and other traditional sys-
tems of medicine, have been of continuous interest as a potential
resource of chemical scaffolds for new antimalarial drugs [16e19].
However a long history of missed opportunities; until quinine and
artemisinin emerged, depicts the challenges involved in the process
[20]. The drug discovery and development from traditionally used
medicinal plants lacked a fast track path. RP; now an organized
trans-discipline, delineates a rapid path for the drug discovery from
traditional medicine. It is not only cost effective but also meets the
challenges of human safety and efﬁcacy [21,22]. RP is, gradually but
steadily, ﬁnding its pace in the global quest for new drugs [23e25].
The antimalarial potential ofN. arbor-tristis has been investigated at
traditionally used ﬁxed dose, for the rigorous scientiﬁc evidence,
for its antiparasitic activity and safety in patients through the
present observational study. Such an observational study to
conﬁrm clinical hits is a prerequisite of RP [26].
The information of N. arbor-tristis in the Ayurveda texts and
vaidyas’ notes and the data in an earlier fairly large experiential
study in 120 patients of malariawith the plant [10,11] prompted the
present in-depth observational study. Twenty patients of malaria
(P. falciparum, P. vivax. or mixed infection); treated with the tradi-
tional ﬁxed dose of leaves of the plant were observed with moreent. Drop in the levels of TNF-a within 24 h was remarkable in all the patients, though
Fig. 9. Shows levels of IL-10, an anti-inﬂammatory cytokines in subset A and B during the treatment. Both the subsets showed decreasing trend, though the change was signiﬁcant
in subset A. It was seen that IL-10 drop was gradual as compared to TNF-a.
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selected markers of the disease severity. The study conﬁrms the
earlier clinical hits, through a complete cure in 50% (10/20) patients
(subset A). Remaining 10 patients (subset B) showed partial
response with early clinical improvement before parasite clear-
ance and gradual decrease in parasite count. Parasite clearance was
initially monitored by slide and by RDT. PCR was used to conﬁrm
the parasite presence, type and clearance; ﬁrst time in a clinical
study of plant for malaria. The results of slide and PCR were well
correlated; whereas occasionally RDT failed to give parasite type
accurately. But there was no falseþ ve or negative either by slide or
RDT when compared the data with PCR (data not shown).
It is important to note that both subsets showed similar drop in
MMS, irrespective of the type of infection and the baseline para-
sitemia. Prakriti analysis of these patients too did not show any
segregation in responders vis-a-vis non-responders (data not
shown). The early clinical response in either subset further re-
ﬂected in an improvement in the various markers of response. Low
platelet count; a hallmark of malaria infection, showed increasing
trend in both the subsets. Elevated lactic acid level in malaria is a
contribution from RBCs, during excessive anaerobic glycolysis by
parasite [27,28] and from the muscles during shivering. Increased
anaerobic glycolysis (in muscles and RBCs) and impaired hepatic
and renal lactate clearance aggravate hypoglycaemia and lactic
acidosis in severe malaria [28]. In the present study only mild to
moderately severe patients were taken; none of them had hypo-
glycaemia or lactic acidosis at the time of admission.
In this study all 8 patients having high baseline lactic acid, also
had moderate (n ¼ 3) to severe (n ¼ 5) chills on 0'day. Reduction in
lactic acid was associated with the relief from chills in all these pa-
tients by 7th day. Five out of these 8 patients also had high AST levels
which dropped by 7 days. This suggests a high lactic acid and AST
level was a contribution from the skeletal muscles during shivering.
Six out of these 8 cases (with baseline high lactic acid) also had low
platelet count and ﬁve of them showed increasing trend.
The safety and tolerability of N. arbor-tristis in all these patients
was closely monitored clinically as well as with the laboratory
markers of organ functions. None of them showed any adverse event
except one patient who developed on the 7th day mild but self-limiting diarrhoea. As in the previous study [10,11], the paste was
generally well accepted, despite its bitter taste and the unfamiliar
paste nature of the formulation. The symptoms of nausea and a bitter
taste inmouth were relieved. There were no hepato- or nephro-toxic
effects as judged by the laboratory monitoring. On the contrary, 15
patients had abnormal levels of one or more markers of liver and
kidney function which improved in all the patients by 7th day. The
hepatoprotective activity of the dried leaves of N. arbor-tristis has
been shown in rats with ethanol extract in carbon tetrachloride
(CCl4)-induced liver damage [29] and with the chloroform extract in
streptozotocin (STZ)-induced diabetes [30]. This suggests the puta-
tive protection from the free radicals, generated by CCl4 and STZ.
The striking feature of the present study was an early amelio-
ration of the disease severity even before the complete parasite
clearance. This was markedly evident in the delayed clinical re-
sponders; n ¼ 10 (4 from subset A and 6 from subset B). This
amelioration of disease severity was not markedly associated with
the type of infection, degree of parasitemia and baseline MS. The
comparative data in two subsets showed signiﬁcant improvement
in all themarkers by seven days in subset A. However, the change in
subset B was not signiﬁcant. This may be due to the high baseline
value in the patients of subset A for most of the markers compared
to subset B, which showed marked improvement. However, in an
observational study individual patient needs a meticulous analysis.
Such analysis showed similar trend in these markers as to subset A.
The studywas conductedwith a ﬁxed dose regimen. There is a need
of dose searching, ﬁnding and optimizing in subsequent studies for
early parasite recovery in the delayed responders. There is also
need to standardise the formulation with concentration of actives.
Phytochemical analysis of plant has shown several compounds viz.
D-mannitol, b-sitosterole, Astragalin, Nicotiﬂorin, Oleanolic acid,
Nyctanthic acid, Nyctanthin, Tannic acid Ascorbic acid Methyl sa-
licylate, Friedeline, Desrhamnosylverbascoside [31,32].
The marked improvement in clinical markers in the patients can
be explained by their cytokine proﬁle. In both the subsets, all the
patients showed marked decrease in TNF-a levels within 24 h. of
treatment. It was interesting to note that, once TNF-a reduced it did
not raise to the baseline level even in the subsequent episodes of
fever, which were milder with reduced severity of the symptoms. On
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inﬂammatory cytokines viz. IL-6 and IFN-gmeasured in these patients
also showed signiﬁcant drop (data not shown). Thus both types of
cytokines maintained inﬂammatory and anti-inﬂammatory balance.
The role of pro-inﬂammatory cytokines in the pathogenesis and
severity of malaria is well documented [33e38]. The development
of symptoms similar to clinical malaria viz. fever, rigors, headache,
myalgia, has been reported in humans with an intravenous infusion
of the recombinant TNF-a [36]. Severe malaria, characterized by
hypotension, thrombocytopenia, pulmonary oedema, was associ-
ated with high levels of TNF-a [37e39]. A burst of TNF-a release
occurs after schizonts rupture from RBCs, with the induction of a
cascade of immune reaction and inﬂammation. A marked decrease
in TNF-a within 24 h could be one of the responsible factors for an
early clinical relief. Immunomodulatory and anti-inﬂammatory
activity of N. arbor-tristis earlier reported in in vivo and in vitro
models at the Central Drug Research Institute [40e43], Industrial
Toxicology Research Centre [44e46] and by others [47e49]. In the
adjuvant arthritis mouse model, the aqueous fraction of the alco-
holic extract (100 mg/kg) decreased TNF-a signiﬁcantly [42e44].
Another study in mice showed inhibition of TNF-a secretion
induced by Staphylococcus aureus-protein [42]. These experimental
data support the present clinical anti-inﬂammatory ﬁndings. In our
laboratory too we have observed a signiﬁcant reduction of TNF-a
secretion from LPS-activated macrophage by several fractions of
the plant (unpublished data).
This immunomodulation may be reﬂected in the early disease-
modifying activity of the plant seen in this study. The importance
of disease-modifying agents to decrease morbidity in severe ma-
laria was emphasized by a group of experts at Dakar [50]. It has also
been suggested that a smaller number of residual parasites may
even assist the development of the host immunity to malaria.
Moreover, this disease-modifying pattern is not seen so commonly
when patients are treated with the standard antimalarials; with CQ
both apyrexia and parasite clearance are concomitant. Not with-
standing a complete parasite clearance with CQ, several symptoms
of illness viz. weakness, fatigue, nausea, loss of appetite etc. are
often persistent. The extracts of N. arbor-tristis have shown anti-
plasmodial activity in vitro cultures (data not shown). This needs to
be followed up with phytoactives.
In summary, meticulous monitoring of several clinical and
biochemical markers helped proving activity of the plant affecting
multiple targets of malarial pathogenesis. It was well tolerated and
found to be safe. The striking observation of the study was early
clinical improvement despite the presence of parasite; which is
partially explained by the marked reduction in inﬂammatory cyto-
kinee TNF-a. Dose searchinge ﬁnding and optimizing evenwith the
paste formulation might give the anticipated faster parasite clear-
ance. The study needs to be further explored for the development of
standardized formulation with optimised dose and also for the
isolation of active compounds to reduce the time of treatment. In this
study, markers of response for antimalarial activity were monitored
intensively and frequently, which was possible in a smaller sample
size. In future, attempts will be made, with a standardized formula-
tion, for a large scale study for disease-modifying activity, parasite
clearance and relapse. The history of antimalarial natural products is
studiedwith examples of substantial delays from their traditional use
to emergence as modern drugs e.g. quinine, and artemisinin. Such
delays can be handled by well-organized and trans-disciplinary RP of
natural products use in traditional medicine.
5. Conclusion
The study shows antimalarial potential of N. arbor-tristis in pa-
tients; conﬁrmed by clinical and parasite markers of response. Thepaste formulation is well tolerated. The study shows a unique
approach, through RP, for drug discovery from an Ayurvedic me-
dicinal plant used for malaria in practice. Further in depth studies
for the development of a standardized phytopharmaceutical are
required.The plant also can be explored for the discovery of a
phytoactive as well as scaffold-based new chemical entities.
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